Literature DB >> 12379718

Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines.

S Raghavan1, M Hjulström, J Holmgren, A-M Svennerholm.   

Abstract

The protective effect of therapeutic oral immunization with homologous and heterologous formalin-inactivated Helicobacter pylori cells given together with cholera toxin as an adjuvant was evaluated with C57BL/6 mice infected with H. pylori Sydney strain 1 (SS1). The bacteria used for immunization were strains that were either homologous or heterologous with regard to the O antigen (i.e., the Lewis antigen [Le antigen]) expressed by the lipopolysaccharide of the infecting H. pylori SS1 strain. We found that repeated oral immunization with inactivated H. pylori SS1 cells can significantly inhibit an existing infection (P < 0.001) and that the protection induced by such therapeutic immunization extends to protection against reinfection (P < 0.001). A similar level of protection was also achieved by immunization with another inactivated H. pylori strain having the same O antigen (Le antigen) as the infecting H. pylori SS1 strain. In contrast, immunization with inactivated strains expressing a heterologous O antigen, Le(x), provided less protection or no protection. Immunization with H. pylori lysate preparations, on the other hand, resulted in significant comparable protection whether the lysates were prepared from an Le(x) strain or an Le(y) strain. Postimmunization gastritis was seen in mice that were protected after vaccination but not in unimmunized or unprotected mice. In conclusion, therapeutic immunization with inactivated H. pylori whole-cell vaccines may provide strong protection both against experimental H. pylori infection and against later reinfection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379718      PMCID: PMC130438          DOI: 10.1128/IAI.70.11.6383-6388.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  An oral B subunit: whole cell vaccine against cholera.

Authors:  J Holmgren; A M Svennerholm; M Jertborn; J Clemens; D A Sack; R Salenstedt; H Wigzell
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria.

Authors:  T H Ermak; R Ding; B Ekstein; J Hill; G A Myers; C K Lee; J Pappo; H K Kleanthous; T P Monath
Journal:  Gastroenterology       Date:  1997-10       Impact factor: 22.682

3.  Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide.

Authors:  I M Simoons-Smit; B J Appelmelk; T Verboom; R Negrini; J L Penner; G O Aspinall; A P Moran; S F Fei; B S Shi; W Rudnica; A Savio; J de Graaff
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

4.  A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain.

Authors:  A Lee; J O'Rourke; M C De Ungria; B Robertson; G Daskalopoulos; M F Dixon
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

5.  Catalase, a novel antigen for Helicobacter pylori vaccination.

Authors:  F J Radcliff; S L Hazell; T Kolesnikow; C Doidge; A Lee
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

Review 6.  Helicobacter pylori and the pathogenesis of gastroduodenal inflammation.

Authors:  M J Blaser
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

7.  Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice.

Authors:  M Mohammadi; S Czinn; R Redline; J Nedrud
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

Review 8.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

9.  Long term serological surveillance after treatment of Helicobacter pylori infection.

Authors:  R A Veenendaal; A S Peña; J L Meijer; H P Endtz; M M van der Est; W van Duijn; F Eulderink; J Kreuning; C B Lamers
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

10.  The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice.

Authors:  R L Ferrero; J M Thiberge; I Kansau; N Wuscher; M Huerre; A Labigne
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

View more
  21 in total

1.  Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase.

Authors:  Carl-Fredrik Flach; Anna Karin Östberg; Anne-Therese Nilsson; Rene De Waal Malefyt; Sukanya Raghavan
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Protease-activated receptor 1 suppresses Helicobacter pylori gastritis via the inhibition of macrophage cytokine secretion and interferon regulatory factor 5.

Authors:  Y-T Chionh; G Z Ng; L Ong; A Arulmuruganar; A Stent; M A Saeed; J Lk Wee; P Sutton
Journal:  Mucosal Immunol       Date:  2014-05-28       Impact factor: 7.313

3.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

4.  Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors.

Authors:  E Strömberg; A Edebo; B S Lundin; P Bergin; M Brisslert; A M Svennerholm; C Lindholm
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

5.  Localized suppression of inflammation at sites of Helicobacter pylori colonization.

Authors:  Alison L Every; Garrett Z Ng; Caroline D Skene; Stacey N Harbour; Anna K Walduck; Michael A McGuckin; Philip Sutton
Journal:  Infect Immun       Date:  2011-08-01       Impact factor: 3.441

6.  Natural killer cells and Helicobacter pylori infection: bacterial antigens and interleukin-12 act synergistically to induce gamma interferon production.

Authors:  Cheol H Yun; Anna Lundgren; Josef Azem; Asa Sjöling; Jan Holmgren; Ann-Mari Svennerholm; B Samuel Lundin
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

Review 7.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

8.  M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens.

Authors:  Yok-Teng Chionh; Janet L K Wee; Alison L Every; Garrett Z Ng; Philip Sutton
Journal:  Infect Immun       Date:  2009-04-20       Impact factor: 3.441

9.  Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice.

Authors:  S Raghavan; M Fredriksson; A-M Svennerholm; J Holmgren; E Suri-Payer
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

10.  Antibody-mediated protection against infection with Helicobacter pylori in a suckling mouse model of passive immunity.

Authors:  Rebecca J Gorrell; Roy M Robins-Browne
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.